Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Claudia Martinelli
Observed name:
C. Martinelli
Institutions:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Scuola Superiore Meridionale
Observed institutions:
University of Messina,
Federico II University Hospital,
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Scuola Superiore Meridionale,
University of Naples Federico II,
Temple University
show all 6
ORCID:
0009-0004-2417-0589
Observed ORCID:
0009-0004-2417-0589
OpenAlex ID:
A5002308610
Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
2020
·
Michela Piezzo
, Stefania Cocco
, et al.
·
International Journal of Molecular Sciences
·
231
PDF
Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis
2024
·
Roberta Caputo
, Giuseppe Buono
, et al.
·
Frontiers in Oncology
·
93
PDF
Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome
2023
·
Linda Cucciniello
, Giovanna Garufi
, et al.
·
Cancer Treatment Reviews
·
79
PDF
CAR-T cell therapy for breast cancer: Current status and future perspective
2024
·
Giuseppe Buono
, Monica Capozzi
, et al.
·
Cancer Treatment Reviews
·
31
Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives
2025
·
Vincenzo Di Lauro
, Alessandro Rizzo
, et al.
·
Cancer Treatment Reviews
·
16
Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors
2023
·
Erica Pietroluongo
, Pietro De Placido
, et al.
·
Journal of Thoracic Oncology
·
10
PDF
Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2− Breast Cancer: A Systematic Review
2025
·
Giuseppe Di Grazia
, Arianna Dri
, et al.
·
Cancers
·
9
PDF
Point-of-Care testing: an ally for precision oncology
2025
·
S. Singh
, P. M. Kalligosfyri
, et al.
·
Annals of Research in Oncology
·
4
PDF
Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study
2025
·
Pietro De Placido
, Rossana Di Rienzo
, et al.
·
European Journal of Cancer
·
4
Abstract PS5-03-15: Real-world outcomes with sacituzumab govitecan in patients with triple-negative breast cancer and central nervous system metastases
2026
·
R. Caputo
, M. Piezzo
, et al.
·
Clinical Cancer Research
·
3
The multidisciplinary management of HER2-positive breast cancer brain metastases: from new biological insights to future therapeutic options
2024
·
Claudia von Arx
, Claudia Calderaio
, et al.
·
Frontiers in Oncology
·
3
PDF
Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion
2023
·
Roberta Caputo
, Giuseppe Buono
, et al.
·
Future Oncology
·
3
Real-world evidence of sacituzumab govitecan in metastatic triple-negative breast cancer: an updated multicenter analysis
2026
·
R. Caputo
, G. Buono
, et al.
·
ESMO Open
·
1
PDF
354P Sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer patients: A multicenter real-world updated analysis
2025
·
R. Caputo
, M. Piezzo
, et al.
·
ESMO Open
·
1
449P Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) treatment in metastatic lobular breast cancer (mLBC): A retrospective cohort study
2023
·
C. von Arx
, A. Calabrese
, et al.
·
Annals of Oncology
·
1
PDF
Unraveling the use of vaccine therapy in HER2-positive breast cancer: a comprehensive review of current state and future perspectives
2026
·
Aldo Caltavituro
, Claudia Martinelli
, et al.
·
Journal of Experimental & Clinical Cancer Research
483P Sacituzumab govitecan in older patients with advanced triple-negative breast cancer: Effectiveness and tolerability in real-world Italian practice
2026
·
G. Buono
, M. Piezzo
, et al.
·
ESMO Open
568eP Early progression to CDK4/6 inhibitors plus endocrine therapy in HR+/HER2− metastatic breast cancer: A real-world analysis
2026
·
M. Tafuro
, M. Piezzo
, et al.
·
ESMO Open
557eP OVAL-T-Dxd: Real-world assessment of ovarian function suppression (OFS) during trastuzumab deruxtecan (T-Dxd) therapy in premenopausal, hormone-receptor–positive (HR+/HER2-Low) metastatic breast cancer (mBC)
2026
·
S. Parola
, O. Tinelli
, et al.
·
ESMO Open
PDF
Abstract PS3-09-18: Early AB-ITALY: Evaluating Real-World Use of Adjuvant Abemaciclib and Drug Interaction Risk in HR+/HER2- early Breast Cancer
2026
·
S. Scagnoli
, M. Verrico
, et al.
·
Clinical Cancer Research
Abstract PS5-03-14: Clinical features and drug-drug interactions of patients treated with Sacituzumab Govitecan for metastatic triple-negative breast cancer: a multicenter correlative real-world updated analysis
2026
·
R. Caputo
, C. Martinelli
, et al.
·
Clinical Cancer Research
Analysis of Large Language Model Decision Making in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer
2026
·
Roberto Buonaiuto
, Aldo Caltavituro
, et al.
·
JCO Clinical Cancer Informatics
PDF
188P Sacituzumab govitecan after immune checkpoint inhibitors in metastatic TNBC: Real-world evidence
2025
·
M. Piezzo
, R. Caputo
, et al.
·
Immuno-Oncology Technology
PDF
373P Association between CDK4/6 inhibitor (i) clinical outcomes and breast cancer (BC) histotypes
2025
·
C. von Arx
, A. Calabrese
, et al.
·
ESMO Open
PDF
209P Comparative analysis of clinician and AI decision-making in HR+/HER2- early breast cancer within routine clinical practice and clinical trial
2025
·
R. Buonaiuto
, R. Di Rienzo
, et al.
·
ESMO Open
PDF
Show more works
View as search
Works count:
25
Citation count:
489
H-index:
7
I10-index:
6
Year
Topic
Type